Bora CDMO Bora CDMO

X

Find Carvedilol Phosphate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Carvedilol Phosphate
Also known as: Carvedilol phosphate, 1196658-85-1, Carvedilol (phosphate hemihydrate), 4s19o2f64l, Bm 14190 (phosphate hemihydrate), 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, phosphate, hydrate (1:1:1)
Molecular Formula
C24H31N2O9P
Molecular Weight
522.5  g/mol
InChI Key
JAYBFQXVKDGMFT-UHFFFAOYSA-N
FDA UNII
4S19O2F64L

Carvedilol Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity. The S enantiomer of carvedilol nonselectively binds to and blocks beta-adrenergic receptors, thereby exerting negative inotropic and chronotropic effects, and leading to a reduction in cardiac output. In addition, both enantiomers of carvedilol bind to and block alpha 1-adrenergic receptors, thereby causing vasodilation and reducing peripheral vascular resistance.
1 2D Structure

Carvedilol Phosphate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol;phosphoric acid;hydrate
2.1.2 InChI
InChI=1S/C24H26N2O4.H3O4P.H2O/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;1-5(2,3)4;/h2-12,17,25-27H,13-16H2,1H3;(H3,1,2,3,4);1H2
2.1.3 InChI Key
JAYBFQXVKDGMFT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.O.OP(=O)(O)O
2.2 Other Identifiers
2.2.1 UNII
4S19O2F64L
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Carvedilol Phosphate

2. 1196658-85-1

3. Carvedilol (phosphate Hemihydrate)

4. 4s19o2f64l

5. Bm 14190 (phosphate Hemihydrate)

6. 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, Phosphate, Hydrate (1:1:1)

7. 2-propanol,1-(9h-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-,phosphate (salt), Hydrate (2:2:1)

8. Unii-4s19o2f64l

9. Schembl599530

10. 309c892

11. Q27260413

12. 1-9h-(carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol Phosphate Hemihydrate

2.4 Create Date
2008-01-22
3 Chemical and Physical Properties
Molecular Weight 522.5 g/mol
Molecular Formula C24H31N2O9P
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count10
Rotatable Bond Count10
Exact Mass522.17671757 g/mol
Monoisotopic Mass522.17671757 g/mol
Topological Polar Surface Area155 Ų
Heavy Atom Count36
Formal Charge0
Complexity557
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameCoreg cr
PubMed HealthCarvedilol (By mouth)
Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
Active IngredientCarvedilol phosphate
Dosage FormCapsule, extended release
RouteOral
Strength10mg; 80mg; 40mg; 20mg
Market StatusPrescription
CompanySb Pharmco

2 of 2  
Drug NameCoreg cr
PubMed HealthCarvedilol (By mouth)
Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
Active IngredientCarvedilol phosphate
Dosage FormCapsule, extended release
RouteOral
Strength10mg; 80mg; 40mg; 20mg
Market StatusPrescription
CompanySb Pharmco

5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Pharmacological Classes
Adrenergic beta1-Antagonists [MoA]; Adrenergic beta2-Antagonists [MoA]; alpha-Adrenergic Blocker [EPC]; beta-Adrenergic Blocker [EPC]; Adrenergic alpha-Antagonists [MoA]
left grey arrow
right gray arrow
  • CAPSULE, EXTENDED RELEASE;ORAL - 10MG
  • CAPSULE, EXTENDED RELEASE;ORAL - 20MG
  • CAPSULE, EXTENDED RELEASE;ORAL - 40MG
  • CAPSULE, EXTENDED RELEASE;ORAL - 80MG
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY